Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Inoviq Ltd ( (AU:IIQ) ) just unveiled an update.
INOVIQ Ltd has appointed Dr. Emma Ball as Chief Commercial Officer, effective April 22, 2025. Dr. Ball brings extensive experience from CSL Ltd and Illumina Inc, and will lead commercial efforts to advance INOVIQ’s technologies and products. Her expertise is expected to significantly impact the company’s strategic partnerships and commercialization efforts, particularly in advancing ovarian cancer screening tests and CAR-exosome therapy for breast cancer.
More about Inoviq Ltd
INOVIQ Ltd is a biotechnology company focused on pioneering next-generation diagnostics and therapeutics for cancer. The company has commercialized its EXO-NET exosome isolation technology for biomarker discovery and diagnostics development, and the hTERT test for bladder cancer. INOVIQ is advancing diagnostics for ovarian and breast cancers and developing early-stage exosome therapeutics for solid tumors.
YTD Price Performance: -31.07%
Average Trading Volume: 120,534
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$39.59M
Learn more about IIQ stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue